New authorization expands the university's scope in Reblas and reinforces the quality control of plant derivatives in the national market

Document developed by a group with 31 Brazilian academic and research institutions points out regulatory barriers and suggests an agile framework to strengthen the scientific and technological sector

After decades of discussions, the agency advances its agenda aiming to create a genetic bank of the plant in Brazil

Judge Vera Lúcia Feil's injunction orders the release of the company's cannabidiol after facing automatic denials from the regulatory agency

The decision from the 16th Federal Court ends the prohibition of flowers and mandates the release of THC and CBD-based products as active ingredients.

The Reporting Minister, Herman Benjamin, acknowledged that no subconstitutional laws are being violated, maintaining what had already been decided at the 5th Region Federal Regional Court (TRF-5)

Dib was one of the main figures behind the regulation of medicinal cannabis use in Brazil and tomorrow he will clarify doubts about the current Anvisa legislation and discuss the agency's perspectives for the coming years regarding the plant

Patients whose data was exposed by the agency fear being targeted for advertising and retaliation

Curitiba welcomes its first exclusive medicinal cannabis pharmacy, in a market that grew from R$ 38.5 million in 2022 to R$ 237.8 million in 2025, while Paraná accounts for only 2.4% of sales, indicating great potential in the state with 11 million inhabitants

Decision reaffirms the six-month deadline for implementing rules on hemp for medicinal, pharmaceutical, and industrial use

"We do not agree, and we will do everything to try to reverse this," says Guilherme Santos, CEO of Hemp Boutique

The topic was discussed during a lecture at the 43rd CIOSP, the largest dentistry congress in Latin America, focusing on scientific evidence and the impacts of Anvisa's new regulation on dental practice in the treatment of orofacial pain

The topic was discussed during a lecture at the 43rd CIOSP, the largest dentistry congress in Latin America, focusing on scientific evidence and the impacts of Anvisa's new regulations on dental practice in the treatment of orofacial pain.

Gustavo Palhares believes that regulatory revision can relax prescriptions, expand access, and raise technical requirements in the medicinal cannabis sector

According to Filipe Campos, from Close-Up International, the market could expand even further with rule updates and greater medical adherence

The President emphasized the responsibility of the appointees and reinforced the importance of the agencies for the country's development

Director-General of the National Narcotics Fund of Colombia, Milver Rojas, states that the process will be immediate once Anvisa confirms and foresees a return to the four to five-day deadline for each authorization

Public hearing will present a balance of the first year of cannabis in the São Paulo SUS and encourage projects in science, innovation, and social impact

Projections indicate accelerated growth of the medicinal cannabis market by 2034, driven by regulatory changes and expanded therapeutic applications

Anvisa proposes exclusive process for the regulation and experts point out impact on the sector